|
Efficacy of Low-Dose versus High-Dose Radioactive Iodine for Thyroid Remnant Ablation in Low- and Intermediate-Risk Papillary Thyroid Carcinoma
|
A Gholami    , A Nourozi , H Gholinia , SH Mousavie Anijdan * |
| 4.Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, I.R.Iran. , shmosavia@gmail.com |
|
|
Abstract: (233 Views) |
Background and Objective: One of the major challenges in the treatment of thyroid carcinoma is selecting the appropriate dose of radioactive iodine for post-surgical thyroid remnant ablation. For patients with low- and intermediate-risk disease, precise determination of the therapeutic dose remains a matter of uncertainty. The aim of this study was to evaluate the effect of low-dose versus high-dose radioactive iodine on treatment outcomes in this group of patients.
Methods: In this retrospective cohort study, 151 patients with thyroid carcinoma were allocated into two groups: a low-dose group (30 mCi) and a high-dose group (100 mCi). Age, sex, physical health status, laboratory markers, iodine-131 whole-body scan findings, and ultrasonography findings were compared between the two groups before radioiodine ablation and at a 1-year follow-up interval.
Findings: A total of 151 patients were enrolled in the study, of whom 124 (82.1%) were female and 27 (17.9%) were male. Based on the first-year follow-up, among the 151 patients studied, 33 patients (21.9%) were classified as having an indeterminate response (IR) and 118 patients (78.1%) as having an excellent response (ER). No significant difference in treatment success was observed between the groups, and the prescribed dose did not have a significant impact on treatment outcomes.
Conclusion: The findings of the present study demonstrated that low-dose radioactive iodine was as effective as high-dose radioactive iodine in achieving successful ablation in patients with initially low- and intermediate-risk thyroid carcinoma. |
Article number: e44 |
| Keywords: Differentiated Thyroid Carcinoma, Radioactive Iodine Therapy, Thyroid Remnant Tissue, Thyroglobulin. |
|
|
Full-Text [PDF 611 kb]
(59 Downloads)
|
Type of Study: Research |
Subject:
Nuclear Medicine
Received: 2025/05/11 | Accepted: 2025/08/16 | Published: 2026/09/20
|
|
|
|
|
|
|
| Send email to the article author |
|
|
